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Summary
Ubiquitination of murine cyclin E is triggered by phosphorylation on threonine 393. Cyclin ET393A knockin mice exhibited
increased cyclin E stability, but no phenotypic abnormalities. Importantly, loss of the p53 pathway exacerbated the effect
of the T393A mutation. Thus, in p21−/− cells the T393A mutation had an exaggerated effect on cyclin E abundance and its
associated kinase activity, which caused abnormal cell cycle progression, and genetic instability involving chromosome
breaks and translocations. Moreover, cyclin ET393A acted synergistically with p53 deficiency to accelerate tumorigenesis
in cyclin ET393A p53−/− mice; Ras more readily transformed cyclin ET393A p53−/− cells than p53−/− cells in vitro; and cyclin
ET393A mice had a greatly increased susceptibility to Ras-induced lung cancer.S I G N I F I C A N C E
The abundance of cyclin E is increased in many human tumors and is predictive of tumor aggression and clinical outcome. However,
it has been uncertain whether elevated cyclin E is a downstream marker for aggressive tumors or represents a driving force behind
tumor progression. Our mouse model strongly supports the latter, by showing that inactivation of the normal pathway for cyclin E
degradation, by direct mutation of the cyclin E gene itself, disrupts cell cycle regulation, causes genetic instability, and is, per se,
oncogenic. Moreover, our mouse model shows that the impact of this misregulated cyclin E is constrained by the p53-p21 pathway,
such that simultaneous loss of p53 and misregulation of cyclin E cooperate to cause oncogenic cell transformation.Introduction
Eukaryotes express regulatory proteins, called cyclins, which
are required for the cell division cycle and function primarily by
binding to and allosterically activating cyclin-dependent ki-
nases (CDKs) (Sherr and Roberts, 1999). Cyclin E1 associates
predominantly with one member of the CDK family, Cdk2, and
serves a dual purpose in activating cell proliferation: it phos-
phorylates and thereby inhibits proteins that impede cell cycle
progression (p27Kip1, pRb), and it phosphorylates and thereby
activates proteins that promote cell division (Hwang and Clur-
man, 2005; Sherr and Roberts, 2004). These functions of cyclin
E are essential when nondividing cells exit the quiescent state
and resume cell proliferation but may be redundant with the
activities of other cell cycle regulators in continuously prolifer-
ating cells (Geng et al., 2003).
Cyclin E expression and its associated kinase activity are
periodic and reach a peak in early S phase (Koff et al., 1992).CANCER CELL : JULY 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIER INC.This periodicity is regulated by E2F-dependent cyclin E tran-
scription (Botz et al., 1996; Geng et al., 1996; Ohtani et al.,
1995) and ubiquitin-mediated cyclin E proteolysis (Clurman et
al., 1996; Won and Reed, 1996). Ectopic overexpression of
cyclin E causes cell cycle anomalies and genetic instability
(Ohtsubo and Roberts, 1993; Spruck et al., 1999; Minella et al.,
2002). It is therefore thought to be critical for normal cells to
tightly regulate cyclin E activity; indeed, increased cyclin E ac-
tivity is a hallmark of cancer cells.
Two ubiquitination pathways promote cyclin E degradation.
Monomeric cyclin E (not bound to cdk2) is targeted by a Cullin-3
ubiquitin ligase (Singer et al., 1999). However, cyclin E that as-
sociates with Cdk2 does not interact with Cullin-3 and instead
is degraded by a pathway involving the SCFFbw7 ubiquitin-pro-
tein ligase (Strohmaier et al., 2001; Koepp et al., 2001; Moberg
et al., 2001). Fbw7 is a bifunctional adaptor that brings phos-
phorylated cyclin E into proximity with the remainder of the
SCF complex. At least four cyclin E phosphorylation sites regu-DOI 10.1016/j.ccr.2005.06.010 35
A R T I C L Elate Fbw7-driven cyclin E ubiquitination; in human cyclin E
these are T62, S372, T380, and S384 (Welcker et al., 2003).
Most important is T380, which is phosphorylated by both
GSK3 and Cdk2 itself. T380 falls within a canonical Fbw7 re-
cognition motif, and T380 phosphorylation allows Fbw7 to bind
to cyclin E (Orlicky et al., 2003; Ye et al., 2004).
Deregulated cyclin E activity is thought to play a fundamental
role in tumorigenesis. A cyclin E transgene that overexpresses
cyclin E induces breast carcinomas in mice, and ectopic cyclin
E overexpression both induces genetic instability in cultured
cells and transforms rodent fibroblasts in combination with
other oncogenes (Bortner and Rosenberg, 1997; Minella et al.,
2002; Spruck et al., 1999). Cyclin E containing a mutation at
T380 that prevents its recognition by Fbw7 was more potent
than wt-cyclin E with respect to causing cell cycle deregulation
and genetic instability.
Many studies have shown that high cyclin E protein expres-
sion in human cancers is associated with increased tumor ag-
gressiveness and poor patient outcome (Keyomarsi et al.,
2002; Porter et al., 1997; Dong et al., 2000; Fukuse et al., 2000;
Hwang and Clurman, 2005). In a few cancers, the cyclin E gene
is amplified, but in most cases cyclin E deregulation may result
from the disruption of pathways that govern its synthesis and
its destruction. Fbw7 mutations have been described in cancer
lines that contain high amounts of cyclin E protein as well as
in primary cancers (Spruck et al., 2002; Strohmaier et al., 2001;
Moberg et al., 2001; Calhoun et al., 2003). Mouse models have
confirmed that Fbw7 is a tumor suppressor gene (Rajagopalan
et al., 2004; Mao et al., 2004).
Although these data support a role for cyclin E in human
tumorigenesis, the effects of cyclin E stabilization in general,
and the specific role of cyclin E deregulation in Fbw7-associ-
ated tumorigenesis remain unclear. On the one hand, the bio-
logical effects of cyclin E stabilization have only been examined
in settings that also involve ectopic cyclin E overexpression.
On the other hand, Fbw7 also targets c-Myc, c-Jun, and Notch
for degradation, and each of these proteins are themselves on-
cogenes when overexpressed (Welcker et al., 2004; Nateri et
al., 2004; Wu et al., 2001). Thus, the neoplasms associated
with Fbw7 loss may result from activation of any (or all) of these
oncogenic targets.
Results
Targeting strategy for cyclin ET393A
We constructed a knockin mouse in which the wild-type cyclin
E gene was precisely replaced with one encoding a nonphos-
phorylatable residue, alanine, at the critical 393 position (equiv-
alent to T380 in human cyclin E). This murine model has two
important features: (1) cyclin E is resistant to Fbw7-mediated
degradation but is transcribed at normal levels from its endog-
enous transcription unit; and (2) the role of disabled cyclin E
turnover is separated from the activities of other oncogenic
Fbw7 substrates caused by mutations within Fbw7 itself. We
created a gene-targeting construct by using site-directed mu-
tagenesis to change threonine 393 in exon 11 of the murine
cyclin E gene to alanine, and by placing a Neor selectable
marker flanked by LoxP sites into the intron between exons 10
and 11 and the gene encoding diphtheria toxin (DTA) upstream36of exon1 (Figure 1). After transfection of embryonic stem (ES)
cells and selection for G418 resistance, the precise replace-
ment of the endogenous cyclin E gene by the cyclin ET393A
allele was confirmed by PCR, Southern blot hybridization, and
then direct genomic DNA sequencing to demonstrate the pres-
ence of the T393A mutation (Figure 1 and data not shown).
Chimeric mice that demonstrated germline transmission of the
cyclin ET393A allele were generated from two such ES cell
clones. To eliminate the Neor marker, cyclin ET393A mice were
mated with MORE mice, in which Cre recombinase has been
targeted to the Mox-2 locus and is therefore expressed early
germ cells (Tallquist and Soriano, 2000). Deletion of the Neor
gene was monitored by PCR amplification and confirmed by
direct DNA sequencing (Figure 1). Mice were then backcrossed
into both 129/SV and C57/Bl6 backgrounds for five genera-
tions.
Interbreeding of cyclin ET393A heterozygous mice led to the
recovery of all expected genotypes with normal Mendelian ra-
tios (Figure 1D). Cyclin ET393A homozygous mice were followed
for 2 years; they displayed no gross phenotypic abnormalities
and appeared indistinguishable from the wild-type littermates.
Detailed histopathological analysis revealed normal morpho-
genesis in all tissues examined. The only significant abnormal-
ity was a mild to moderate splenomegaly (1–2× weight) with
mild extramedullary hematopoiesis. The cyclin ET393A mice dis-
played a normal life span with no significant predilection for
hyperproliferative lesions or tumors.
Expression and activity of cyclin ET393A
The effect of the cyclin ET393A mutation on the expression of
endogenous cyclin E, its associated kinase activity, and cell
cycle regulation was studied in endogenous mouse tissues and
embryonic fibroblasts (MEFs) isolated from day 12–14 em-
bryos. The cyclin E protein was readily detected in extracts
prepared from the spleen and thymus from 2- to 4-month-old
mice, tissues with many proliferating cells (Figure 2A). How-
ever, the level of cyclin E and its associated kinase activity in
the nonproliferative tissues from 2- to 4-month-old mice in-
cluding lung, liver, and kidney was below the limit of detection
(data not shown). Most strikingly, the abundance of the cyclin
E protein in the splenic extracts from cyclin ET393A mice consis-
tently showed a 5- to 10-fold increase compared to age-
matched wild-type controls, while a more limited 2- to 3-fold
elevation in the level of cyclin E was detected in cyclin ET393A
thymic extracts. The amount of cyclin E-associated kinase ac-
tivity closely paralleled the amount of cyclin E protein (Figure
2A). Consistent with the increase in cyclin E protein levels,
freshly isolated ET393A splenocytes showed a 4-fold increase in
the number of cycling cells compared to matched wild-type
splenocytes (Figure 2B). Histologic examination of the corre-
sponding splenic sections, performed to rule out an occult ma-
lignancy, showed only a mild increase in extramedullary hema-
topoiesis. Fractionation of the spleen into populations enriched
for either B or T lymphocytes showed that cyclin ET393A was
elevated equally in both compartments (data not shown).
A small increase in cyclin E protein abundance and its asso-
ciated kinase activity (1.5–2.2×) was detected in asynchro-
nously proliferating heterozygous and homozygous cyclin
ET393A MEFs (Figure 2C). This appeared to be due to a small
increase in the half-life of cyclin ET393A (5 hr) in comparison to
wild-type cyclin E (4 hr), as determined both by 35S pulse-CANCER CELL : JULY 2005
A R T I C L EFigure 1. Construction of a cyclin ET393A knockin mouse
A: The targeting construct encoding the murine cyclin E gene modified to express a cyclin ET393A. Arrowheads designate LoxP sites, and arrows designate
PCR primer sites. DTA, diphtheria toxin gene.
B: Southern blot of murine genomic DNA from embryonic stem cell clones selected for homologous integration of the cyclin ET393A targeting construct. The
DNA was digested with SpeI that cuts within the Neor gene and once downstream of the cyclin E gene, which falls outside of the targeting construct.
Probe was from a murine cyclin E cDNA corresponding to exon 11. The band predicted for homologous integration of the cyclin ET393A transgene is
observed in lanes 2, 3, and 6.
C: PCR genotyping. Both wild-type and cyclin ET393A are detected following Cre-mediated recombination. DNA with cyclin ET393A is larger based on the
presence of an additional 150 bp derived from the LoxP DNA, which are present in the terminal intron after targeting.
D: Cyclin ET393A heterozygous matings result in the normal Mendelian ratio of expected genotypes.chase measurement and by cycloheximide-mediated inhibition
of protein synthesis (Figures 2D and 2E), whereas the amount
of the cyclin ET393A mRNA was unchanged compared to wild-
type cyclin E (data not shown). The surprisingly small effect of
the T393A mutation on cyclin E stability in MEFs is explained
by the assembly of most cyclin E protein into catalytically in-
active complexes with the CDK inhibitor p21Cip1, which stabi-
lizes cyclin E through the inhibition of its associated kinase ac-
tivity, and is addressed in greater detail below (Clurman et al.,
1996; Welcker et al., 2003). The stability of cyclin ET393A was
still regulated by ubiquitin-dependent degradation, since pro-
teasome inhibition increased the half-life of cyclin ET393A from
5 hr to greater than 8 hr (data not shown). The modestly in-
creased amount of cyclin ET393A was not associated with a
consistent change in the distribution of MEFs into the G1, S,
or G2/M compartments of the cell cycle (data not shown).
We also examined the expression and activity of cyclin E in
early passage MEFs that were synchronized by serum starva-
tion/contact inhibition and then released into normal growth
medium (Figure 3A). Note that, in contrast to similar experi-
ments performed using human cell lines, the amount of cyclin
E protein in primary MEFs was close to invariant throughout
the cell cycle, with a small peak in S phase. Cyclin E-associ-
ated kinase activity was more periodic than its overall protein
abundance and was limited to late G1 and S phase (Figures
3A and 3B). The cyclin ET393A protein was more abundant, and
its associated kinase activity was both higher and somewhat
less periodic than the wild-type cyclin E protein and kinase
activity. Parallel cultures were pulse labeled with BrdU and har-
vested for flow cytometry to determine the effect of the T393A
mutation on progression through the cell cycle. In these earlyCANCER CELL : JULY 2005passage MEFs, the premature activation of cyclin ET393A-asso-
ciated kinase activity did not have a reproducible effect on the
rate at which cells completed G1 and entered S phase (Fig-
ure 3C).
The elevated level of cyclin ET393A detected in splenic ex-
tracts suggested that loss of the T393 phosphorylation might
have a significant effect on lymphocyte activation and prolifera-
tion. Resting T lymphocytes expressed barely detectable levels
of cyclin E. Following activation, the level of cyclin ET393A in-
creased earlier and to a greater extent than wild-type protein
(Figure 3D). This resulted in an increase in the percentage of
cells activated by a mitogenic stimulus (IL-2 receptor expres-
sion) and in the rate of cell proliferation (Figures 3E and 3F).
These observations were consistent with the splenomegaly
found in cyclin ET393A mice.
Cellular immortalization enhances the effect
of cyclin ET393A
Cyclin ET393A had a much more significant effect on cell prolif-
eration of MEFs immortalized by a 3T3 protocol. The prolifera-
tion of control and cyclin ET393A MEFs entered a plateau be-
tween passages 5 and 10. In most experiments, the cyclin
ET393A MEFs resumed exponential proliferation between pas-
sages 15 and 25, while the control cells frequently remained in
the plateau phase until passages 25–30. A representative result
is shown (Figure 4A). This escape from senescence is a
stochastic process with considerable variability among geneti-
cally identical clones of fibroblasts. Nevertheless, the cyclin
ET393A fibroblasts typically immortalized earlier than control
cells.
After immortalization, cyclin ET393A MEFs grew faster and to37
A R T I C L EFigure 2. Analysis of cyclin ET393A expression and stability in tissue and cultured fibroblasts
A: Splenic and thymic extracts from age-matched mice (8–12 weeks) of indicated genotypes were assayed for cyclin E level by Western blot. Grb-2 was
used as a loading control. Cyclin E-associated kinase activity was determined from anti-cyclin E immunoprecipitation of the splenic lysate using histone
H1 as substrate.
B: Expression of cyclin ET393A triggers a 4-fold increase in proliferating splenocytes. Splenocytes pooled from three mice of similar ages (2–4 months) were
stained with propidium iodide (PI) and analyzed by flow cytometry.
C: Asynchronously proliferating cyclin ET393A MEFs have increased cyclin E protein and associated kinase activity. Western analysis of early passage (P2)
cycling MEFs stained with anti-cyclin E antibody. Tubulin was used as loading control. Cyclin E-associated kinase activity was measured from anti-cyclin
E-immunoprecipitated complexes. Kinase activity was quantified by phosphorimaging.
D: Effect of p21 on cyclin E stability. Cycloheximide half-life of cyclin E was determined by Western blot analysis of S phase-enriched MEFs. Synchronized
MEFs (serum starvation) were released, grown for 20 hr, and exposed to cycloheximide for the indicated times.
E: Asynchronously proliferating MEFs were pulse labeled with 35S-methionine and harvested at the indicated times. The amount of labeled cyclin E was
determined by phosphorimage analysis of anti-cyclin E-immunoprecipitated extracts that had been resolved by SDS-PAGE.a 2-fold greater saturation density (data not shown) than the
immortalized control MEFs. The amount of cyclin E protein was
also considerably greater in the cyclin ET393A immortalized
MEFs compared to control immortalized MEFs (Figure 4B), and
this was associated with an earlier entry into S phase in syn-
chronized cells (Figure 4C).
Interaction of cyclin ET393A with the p53-p21 pathway
Our results suggested that the biological effects of cyclin
ET393A were being constrained in early passage cells by a fac-
tor(s) that was lost upon immortalization. One candidate was
the CDK inhibitor p21Cip1, which has previously been shown
to limit the effects of misregulated cyclin E in transfected cells
(Minella et al., 2002). In the immortalized cells described above,
p21 levels were reduced (data not shown), presumably as a
secondary effect of p53 inactivation.
To investigate the role of p21 in controlling cyclin E activity,
we crossed the ET393A allele into a p21 null background. In38most tissues, the amount of cyclin ET393A and its associated
kinase activity were similar in cyclin ET393A and cyclin ET393A
p21−/− mice (Figure 2A). In early passage MEFs, however, the
loss of p21 had a significant impact on the abundance and
activity of cyclin ET393A relative to wild-type cyclin E. As pre-
viously reported, cyclin E protein levels were greatly reduced
in p21 null MEFs, and its half-life was reduced to 2 hr (Figures
4D, 4E, 2D, and 2E) (Welcker et al., 2003). This was thought to
be caused by an increase in CDK2-dependent phosphorylation
of cyclin E, and an increase in its rate of degradation by the
T393-dependent pathway. Consistent with this idea, the sta-
bility and abundance of cyclin ET393A was largely unaffected by
the loss of p21 (Figures 4D, 4E, 2D, and 2E), and as a conse-
quence it was both more stable (Figures 2D and 2E) and more
abundant (Figures 4D and 4E) than wild-type cyclin E in the
p21 null background.
The increased amount of cyclin ET393A in p21 null MEFs
correlated with both an increased amount of cyclin E-associ-CANCER CELL : JULY 2005
A R T I C L EFigure 3. Effect of cyclin ET393A on cell cycle regulation
A: Synchronized cyclin ET393A and wild-type MEFs were released by serum stimulation and harvested at the indicated times. Cyclin E level was determined
by Western blot analysis of cell lysates. Tubulin was used as loading control. Anti-cyclin E-immunoprecipitated extracts were assayed for kinase activity.
B: Cyclin E-associated kinase activity from A was quantified by phosphorimage analysis.
C: Parallel cultures of synchronized cyclin ET393A and wild-type MEFs were released by serum stimulation and pulsed with BrdU (100 m) for 1 hr prior to
harvest. Nuclei prepared from ethanol-fixed cells were stained with anti-BrdU and PI and analyzed by flow cytometry. Percent BrdU-labeled cells was
determined using CellQuest software.
D: Pooled unfractionated splenocytes (three mice per genotype) were activated with PMA-P (10 g/ml) plus mouse recombinant IL-2 (50 ng/ml). Cells
were harvested and lysed on the indicated days postactivation. Cyclin E level was determined by Western blot using Grb-2 as a loading control.
E: Enriched T cell splenocytes were activated with PMA-P and IL-2. Live cell counts were performed at the indicated times by trypan blue exclusion. Data
are derived from pooled splenocytes isolated from three mice (2–4 months) for each genotype. The results are representative of those obtained from
multiple independent experiments.
F: Percentage of S/G2 nuclei (upper panels) and activated T cells (lower panels). Day 3 (postactivation) growing T cells from each genotype were isolated,
and nuclei were prepared and stained with PI. Parallel day 3 cells were isolated and stained with PE-fluorochrome-conjugated, anti-mouse IL-2R. Activated
cell number was determined by flow cytometry using CellQuest software.ated kinase activity (Figures 4E and 4F) and increased rate of
progression from quiescence to S phase (Figure 4G). Note that
the cyclin ET393A p21−/− cells remained in S phase with a high
percentage (60%) of BrdU-labeled cells at late time points,
while the number of BrdU-positive p21−/− fibroblasts started to
decline. This pattern suggested that the cyclin ET393A induced
both early entry into and delayed progression through S phase
in a p21 null background, similar to what has been seen in cells
overexpressing wild-type cyclin E (Ohtsubo and Roberts, 1993;
Minella et al., 2002; Ekholm-Reed et al., 2004).
In summary, our data showed that induction of p21Cip1
could suppress the effect of the cyclin ET393A mutation. When
p21 expression was reduced, either indirectly during spontane-
ous immortalization or by direct genetic targeting, this pheno-
typic suppression was lost, resulting in greater cyclin E levels,
higher amounts of cyclin E-associated kinase activity, and ab-
errant timing of S phase initiation and completion.CANCER CELL : JULY 2005In contrast to cultured fibroblasts, the level of p21 in wild-
type splenic extracts or resting splenocytes was undetectable
prior to cell activation (data not shown). Moreover, the level of
p21 expressed in activated wild-type splenocytes was 5- to
10-fold lower than that in proliferating MEFs. The preferential
effect of cyclin ET393A on splenocytes of wild-type mice was
therefore consistent with our data showing that the conse-
quences of this mutation were increased in p21-deficient cells.
Cyclin E misregulation causes genetic instability
Whereas cyclin ET393A slightly increased the rate of proliferation
of early passage control MEFs, it significantly inhibited prolifer-
ation of p21 null cells (Figures 5A and 5B). In contrast, cyclin
ET393A significantly increased the proliferation rate of p53 null
MEFs (cyclin ET393A p53−/−), thereby recapitulating the pheno-
type that we observed in spontaneously immortalized cells
(Figure 5C). Thus, decreased p21 expression removed an in-39
A R T I C L EFigure 4. Effect of cyclin ET393A on cycle regulation in spontaneously immortalized and p21 null MEFs
A: Growth curves of cyclin ET393A and wild-type MEFs cultivated according to a 3T3 protocol. Total cell number was determined from cell count and
dilution at each passage.
B: Spontaneous immortalized MEFs (passage 32) were synchronized by serum starvation, released into normal media, and harvested at the indicated
times. Cyclin E level was determined by Western blot using tubulin as loading control.
C: Parallel cultures of synchronized immortal MEFs were pulsed with BrdU (100 m) for 1 hr prior to harvest. Nuclei were stained with anti-BrdU and PI and
analyzed by flow cytometry. The results are representative of those obtained from multiple independent experiments.
D: Western blot detection of cyclin E in asynchronously proliferating early passage MEFs of the indicated genotypes. Grb-2 is a loading control.
E: MEFs of the indicated genotypes were synchronized by serum starvation, released, and harvested at the indicated times. Cyclin E level was determined
by Western blot analysis of cell lysates. Lanes were normalized for total protein and confirmed by parallel Western blots stained for tubulin. Cyclin
E-associated kinase activity was measured in an anti-cyclin E immunoprecipitate kinase assay.
F: Cyclin E-associated kinase activity from A was measured using phosphorimage analysis.
G: Parallel cultures of synchronized MEFs were released from quiescence by serum stimulation and pulse labeled with BrdU (100 m) for 1 hr prior to
harvests. Nuclei harvested from ethanol-fixed cells were stained with anti-BrdU and PI and then analyzed by flow cytometry. The percent of BrdU-positive
cells was determined by CellQuest software.trinsic constraint on cyclin E activity, but this was associated
with enhanced cell proliferation only if p53 was inactive.
We next looked at long-term growth and senescence in a
3T3 protocol (Figure 5D). p21 null MEFs underwent a very tran-
sient senescence with minimal morphologic changes. In con-
trast, p21 null cells expressing cyclin ET393A showed a pro-
nounced defect in proliferation rate and grossly altered cell
morphology, from which they did not recover for at least 15
passages.
The slow growth of cyclin ET393A p21−/− MEFs was associ-
ated with the accumulation of DNA damage. Phosphorylation
of p53 on serine 15 is a sensitive indicator of DNA damage
(Giaccia and Kastan, 1998). Asynchronously proliferating cyclin
ET393A p21 null fibroblasts had an elevated amount of serine
15-phosphorylated p53 compared to p21 null fibroblasts (Fig-
ure 5E, compare lanes 1 and 3). Following irradiation, the level
of p53 phosphorylated on serine 15 was elevated to a similar40extent in both genotypes (Figure 5E, compare lanes 2 and 4).
Using synchronized cells, we found that p53 serine 15 phos-
phorylation occurred in late S phase, with a slightly earlier ap-
pearance and increased abundance of p53 phosphorylation in
the cyclin ET393A p21−/− MEFs (data not shown). The increased
spontaneous phosphorylation of p53 was dependent on the
absence of p21, because the amount of serine 15-phosphory-
lated p53 in cyclin ET393A cells was very low and comparable
to that of control MEFs (data not shown). This was consistent
with our other observations showing that the abnormal activity
associated with cyclin ET393A was constrained by p21.
The slowing of S phase progression and the induction of the
p53 response suggested that cyclin ET393A might be inducing
DNA damage. Direct evidence for cyclin ET393A-dependent ge-
netic instability emerged from flow cytometric and cytogenetic
analyses. At early passages, there were an increased number
of cyclin ET393A p21−/− cells with a tetraploid DNA content,CANCER CELL : JULY 2005
A R T I C L EFigure 5. Expression of cyclin ET393A in p21 null
MEFs inhibits cell growth
A–C: Short-term growth curves of MEFs of the in-
dicated genotypes.
D: Growth curve of cyclin ET393A p21−/− and
p21−/− MEFs cultivated according to a 3T3 pro-
tocol. Total cell number was determined from
cell count and dilution at each passage. The
data represent a single experiment that has
been repeated several times with different MEF
isolates.
E: Western blot of p53 phosphorylated on serine
15 in asynchronously proliferating cultures of p21
cyclin ET393A p21−/− (lanes 1 and 2) and cyclin
ET393A p21−/− MEFs (lanes 3 and 4) that were
either mock irradiated (lanes 1 and 3) or irradi-
ated (lanes 2 and 4). Irradiated cell were har-
vested 24 hr after exposure to 10 Gy.while at later passages an aneuploid population accumulated
(Figure 6A). In comparison, parallel cultures of p21 null fibro-
blasts were stably diploid. To expand these findings, we per-
formed cytogenetic studies on midpassage MEFs (passage 4
and 14), which showed that cyclin ET393A caused the accumu-
lation of a plethora of unstable chromosomal aberrations de-
fined as chromatid/chromosome breaks, gaps, and radial fig-
ures in both p21 null and p53 null backgrounds (Figures 6B
and 6C and Table S1). The presence of stable karyotypic ab-
normalities in cells expressing cyclin ET393A was confirmed by
spectral karyotyping (SKY) analyses (Figure 6D). These data
are consistent with the findings that ectopic cyclin E overex-
pression induces genetic instability in primary human cells only
after disruption of the p53-p21 pathway (Minella et al., 2002).
Cyclin ET393A is an oncogene
That fact that cyclin ET393A could promote genetic instability in
vitro suggested that the mutation might be oncogenic. As an
initial test of this hypothesis, we scored the ability of cyclin
ET393A to cooperate with activated H-RasG12V and p53 defi-
ciency to promote the formation of transformed cell foci in vi-
tro. Transfection of p53 null MEFs with activated H-RasG12V
resulted in the appearance of multiple foci of transformed cells
after 2–3 weeks of growth in culture. Strikingly, the p53 null
MEFs expressing ET393A were hyperresponsive to transforma-
tion by activated H-Ras (Figure 7A). Transfection efficiencies
were comparable, since parallel control cells transfected with
β-galactosidase showed similar transfection efficiency in both
p53 null cell lines (data not shown). Stable expression of acti-
vated H-Ras in p53 null MEFs expressing ET393A produced a
striking morphologic change with abundant rounded cells (Fig-
ure 7B) and a 3-fold increase in mitotic figures (data not
shown). The H-RasG12V p53−/− cyclin ET393A cells exhibited only
a small increase in proliferation rate compared to cells express-
ing wild-type cyclin E (Figure 7C) but had a saturation density
at confluence that was 2- to 4-fold greater (Figure 7E). Parallel
cytogenetic studies showed a large (2- to 3-fold) increase in
chromosomal aberrations in the cells expressing cyclin ET393ACANCER CELL : JULY 2005when compared to H-RasG12V p53−/− MEFs expressing wild-
type cyclin E (Figure 7D). The number of radial figures and
chromatid breaks were selectively elevated. Thus, the trans-
forming effect of cyclin ET393A was reflected in its ability to in-
duce genetic instability and its effects on cell proliferation.
To extend these in vitro results to in vivo models of tumori-
genesis, we investigated the ability of cyclin ET393A to promote
tumorigenesis both in p53 null mice and in mice expressing
activated Ras. We found that cyclin ET393A caused a statistic-
ally significant acceleration of tumorigenesis in the already
highly tumor-prone p53 null background (p = 0.05). Thus, cyclin
ET393A p53−/− mice had a mean tumor-free survival of 145 days
compared to 180 days in p53 null mice (Figure 8A). This accel-
eration of tumorigenesis was comparable to the effect ob-
served when p53 deficiency was combined with p27 deficiency
(Philipp-Staheli et al., 2004). There was no difference in the
spectrum of tumors that developed in p53−/− versus cyclin
ET393A p53−/− mice.
As a further test of its ability to promote oncogenic trans-
formation and promote genetic instability in vivo, we intro-
duced the cyclin ET393A allele into mice that harbored a latent,
spontaneously activated allele of activated K-RasG12D (John-
son et al., 2001). Expression of activated K-Ras results in the
development of multiple lung adenomas and adenocarcinomas
with near 100% penetrance. Expression of the cyclin ET393A
mutation in conjunction with activated K-Ras resulted in a dra-
matic increase in tumor-associated mortality with a mean sur-
vival of just 160 days compared to 260 days with activated
K-Ras alone (Figure 8B). The expression of cyclin ET393A did
not affect tumor morphology; the tumors varied from low-grade
adenomas to adenocarcinomas with focal areas of moderate
to high-grade dysplasia (Figure 8C). Young mice harvested be-
tween 2 and 4 months showed multiple tumors with a trend
toward a higher number of foci in the mice expressing cyclin
ET393A. The tumor burden in advanced-stage mice was difficult
to determine because of tumor coalescence. Figure 8C shows
representative examples of lungs harvested from 7-month-old41
A R T I C L EFigure 6. Cyclin ET393A expression in p21 null MEFs triggers genomic instability
A: Cell cycle profiles of early (P4) and late (P14) cyclin ET393A p21−/− and p21−/− MEFs.
B: Metaphase spread of late passage (p16) cyclin ET393A p21−/− MEFs (unbanded) showing a representative chromosome break and gap (arrows).
C: Metaphase spread of late passage (p16) cyclin ET393A p21−/− MEFs (C banding stain) showing a radial figure and dicentric chromosome (arrow).
D: Spectral karyotyping analysis (SKY) of early passage (p4) wild-type and cyclin ET393A p21−/− and late passage (p13) cyclin ET393A p53−/− MEFs. Representa-
tive chromosome rearrangements detected in cells expressing cyclin ET393A are shown.K-RasG12D mice expressing wild-type cyclin E and cyclin
ET393A.
To determine the effect of cyclin ET393A on genetic instability
during tumorigenesis, in vivo tumors from age-matched ani-
mals were analyzed by array-based comparative genomic hy-
bridization (array CGH). Two of six cyclin ET393A K-rasG12D
tumors showed significant gains and losses of whole chromo-
somes (Figure 8D). A third cyclin ET393A tumor also showed
evidence of chromosome instability, but chromosome gains
and loses in this tumor were less prominent (data not shown),
perhaps due to clonal heterogeneity or contaminating nonneo-
plastic cells. In contrast, no chromosome changes were de-
tected in any of the five K-rasG12D, wild-type cyclin E tumors
we analyzed.
Discussion
The key question we address in these studies is whether tar-
geted misregulation of the murine cyclin E protein expressed
from its endogenous locus is sufficient to cause abnormal cell
cycle progression and genetic instability and promote onco-
genic cell transformation. Previous studies have shown that in-
creased amounts of cyclin E can cause cell cycle abnormalities
and induce tumorigenesis. However, this conclusion was
based on ectopic overexpression studies in cell culture and42transgenic mouse models, both of which involve the analysis
of cyclin E levels that vastly exceed the amount expressed in
a normal cell. This idea also emerged from the complex pheno-
type associated with inactivation or reduced expression of the
Fbw7 gene product, a protein that plays a critical role in cyclin
E ubiquitination and degradation. In fact, Fbw7 is mutated in
several epithelial cancers including breast, ovary, pancreatic,
and endometrial carcinoma (Spruck et al., 2002; Strohmaier et
al., 2001; Moberg et al., 2001; Calhoun et al., 2003). However,
in addition to cyclin E other regulatory proteins are ubiq-
uitinated by Fbw7, including Notch, Myc, and Jun, all of which
have been implicated in tumorigenesis. Therefore, the pheno-
type caused by Fbw7 mutations may depend on its effects on
several downstream effectors.
To circumvent these ambiguities, and to directly examine the
consequences of cyclin E misregulation, we have taken the ap-
proach of specifically disrupting the normal degradation of
cyclin E by the ubiquitin-proteasome system, by constructing a
mouse model in which the wild-type cyclin E gene is precisely
replaced with one encoding alanine instead of threonine at po-
sition 393. Our results show that this single amino acid change
is sufficient to stabilize cyclin E, and in some settings to induce
cell cycle misregulation, genetic instability, and tumorigenesis.
The magnitudes of these effects are highly tissue specific, and
in many cell types this mutation has only minor consequences.CANCER CELL : JULY 2005
A R T I C L EFigure 7. Cyclin ET393A promotes H-RasG12V-mediated transformation
A: Focus formation by cyclin ET393A p53−/− and p53−/− MEFs that had been transfected with activated H-RasG12V. Foci were visualized by staining cells with
crystal violet.
B: Early passage p53−/− MEFs expressing wild-type or cyclin ET393A were infected with retrovirus encoding activated H-RasG12V. Image is a phase contrast
micrograph (200×) showing a large number of refractory and rounded cells expressing cyclin ET393A.
C: Short-term growth curve of H-RasG12V-infected MEFs of the indicated genotypes.
D: C banded metaphase spreads from exponentially growing early passage MEFs (P7) of the indicated genotypes were screened for unstable chromo-
some aberrations as described above. Data are derived from analysis of 45 to 70 cells per genotype and are expressed as aberrations per chromosome
because of the large number of tetraploid cells. Cells undergoing mitotic catastrophe with numerous aberrations were excluded from the analysis.
E: Early passage MEFs of the indicated genotypes were plated at 1 × 106 cells per 10 cm plate. Cells were grown for 10 days with fresh media every third
day. Day 10 cell count was determined by trypan blue exclusion. The data represent a single experiment that has been repeated several times with
similar results.For example, T393A mutation causes a 5- to 10-fold increase
in cyclin E abundance in the spleen but only a 2-fold increase
in the thymus and MEFs. In MEFs, this modest effect of the
cyclin ET393A mutation on cyclin E protein level correlates with
a similarly small effect on cyclin E stability and essentially no
effect on cell cycle progression, whereas a more substantial
effect on cell proliferation is evident in splenocytes. Our data
indicate that this could be explained by the relative paucity of
p21 in resting or activated splenocytes, and hence the dif-
ferential activity of cyclin ET393A in these compared to other
cells.
Overall, the endogenous expression of cyclin ET393A by itself
has very little impact on mouse physiology or cell cycle regula-
tion. Cyclin ET393A mice live a normal life span with no significant
spontaneous tumors or hyperproliferative lesions. Therefore, un-
der ordinary circumstances the T393-dependent degradationCANCER CELL : JULY 2005pathway contributes minimally to cell cycle regulation. These
results raise the question of whether the tumor-prone pheno-
type of Fbw7 mutant mice (Mao et al., 2004) is due to its effects
on cyclin E alone. Nevertheless, in some biological contexts
this pathway is crucial. For example, in certain genetic back-
grounds or in response to physiological stresses (e.g., preg-
nancy) cyclin ET393A mice had a high incidence of massive
splenomegaly, in which the spleens increased 10- to 20-fold
their normal size in conjunction with exuberant extramedullary
hematopoiesis (unpublished data). Moreover, splenic extracts
from these mice had enormously elevated amounts of cyclin E
and associated kinase activity. The specific factors that trig-
gered this phenotype are not yet known, but it nonetheless
illustrates the precarious state of cell cycle regulation when this
pathway for cyclin E degradation absent.
The interaction between cyclin ET393A and the p53-p21 path-43
A R T I C L EFigure 8. Cyclin ET393A promotes tumor growth and genetic instability in vivo
A: Kaplan-Meier survival curve of cyclin ET393A p53−/− and p53−/− mice. The median time of survival was 145 days for cyclin ET393A p53−/− and 180 days for
p53−/− mice. The entire cohort of 43 cyclin ET393A p53−/− mice and 23 p53−/− mice were monitored for tumor morbidity or spontaneous death over a period
of 2 years. Tumors were confirmed by histopathological analysis. Log rank test analysis showed a significant difference between the survival time of cyclin
ET393A p53−/− and p53−/− (p = 0.05). Both genotypes were backcrossed for greater than five generations into C57BL/6 background.
B: Kaplan-Meier survival curve of cyclin ET393A K-RasG12D and K-RasG12D mice. The median time of survival was 160 days for cyclin ET393A K-RasG12D and 260
days for K-RasG12D mice. The entire cohort of 36 cyclin ET393A K-RasG12D and 44 K-RasG12D were monitored for tumor morbidity, respiratory distress, and
spontaneous death over a period of 2 years. Lung tumors were confirmed by histopathological analysis. All mice died of respiratory insufficiency caused
by lung tumor burden. Both genotypes were backcrossed into a pure 129/SJ background.
C: Examples of macroscopic and hematoxylin and eosin (H&E)-stained cross-sections of lung tumors found in K-RasG12D and cyclin ET393A K-RasG12D mice.
The macroscopic images show the entire lung with attached heart (top) isolated from age-matched mice (7 months). The tumors appear as pale white
nodules on the pleural surface. The microscopic sections (lower panels) show two representative tumor nodules with focal areas of organoid morphology
and focal dysplasia. Magnification, 200×.
D: Array CGH results for representative lung neoplasms from cyclin ET393A K-RasG12D (tumors 1 and 2) and K-RasG12D mice (tumors 3 and 4). The normalized
log2 ratio of fluorescence intensity in tumor versus normal reference DNA is on the y axis, and chromosome identification is shown on the x axis at the
bottom. Cyclin ET393A K-RasG12D neoplasms demonstrate whole chromosome gains or losses, consisting of gains of chromosomes 6, 14, 16, and 18 in one
tumor (tumor 1, arrows), and gain of chromosome 6 and loss of chromosome 18 in another tumor (tumor 2, arrows). Gain of the X chromosome due to
sex mismatch between one of the tumors and normal 129 male reference DNA serves as an internal control (tumor 1, arrowhead). In contrast, no definite
chromosomal gains or losses are seen in neoplasms from K-RasG12D mice (tumor 3 and tumor 4).way of CDK inhibition and cell cycle regulation points to an-
other setting where normal cyclin E degradation becomes
essential. Our data showed that loss of the p53-p21 pathway
cooperated with the cyclin ET393A mutation to severely affect
cell proliferation and promote cell transformation. An interac-
tion between these pathways was first observed in cultured
cells ectopically overexpressing wild-type cyclin E or cyclin
ET393A (Minella et al., 2002) and was reinforced by our observa-
tions on the phenotypes of spontaneously immortalized cyclin
ET393A MEFs, which most often involve p53 inactivation and
p21 downregulation. Immortalized cyclin ET393A MEFs had a44substantially higher level of cyclin E than did control MEFs, and
this was associated with increased cell proliferation, growth to
higher cell density, and early transit into S phase. The rate of
immortalization was also increased by the cyclin ET393A muta-
tion. We have not yet determined whether this was due to an
increased rate of p53 inactivation, although this seems likely.
Therefore, not only did the loss of the p53-p21 pathway in-
crease the effect of the T393A mutation, but this mutation may
have a sufficient destabilizing effect on its own to promote p53
inactivation. Hence, these two oncogenic pathways were mu-
tually reinforcing.CANCER CELL : JULY 2005
A R T I C L ETo address more directly whether the increased impact of
the cyclin ET393A mutation on immortalized cells was linked to
loss of the p53-p21 pathway, we crossed the cyclin ET393A al-
lele into p53 and p21 null backgrounds. Similarly to what we
observed in immortalized cells, cyclin ET393A was significantly
more stable, expressed at a higher steady-state level, and had
a greater amount of associated kinase activity than wild-type
cyclin E in the p21 null background. Moreover, these changes
were associated with an early entry into and delayed exit from
S phase. Unlike immortalized MEFs, however, the cyclin ET393A
p21−/− MEFs had a severe proliferation defect, which was evi-
dent both in short-term proliferation assays and in longer-term
propagation by a 3T3 protocol. This correlated with activation
of the p53 DNA damage response and the onset of significant
genetic instability that was manifest by the accumulation of
both unstable and stable chromosome aberrations. Thus, p21
limited the activity of the deregulated cyclin E and thereby
safeguarded against the effects it can have on the cell division
cycle. Note that cyclin ET393A-associated kinase activity was
elevated both in wild-type and in p21 null MEFs, yet its delete-
rious affects on cell proliferation and chromosome stability
were evident only in the latter. Therefore, a function of p21 in
this setting was not just to limit the activity of cyclin E per se,
but also to indirectly control its downstream effects on cell cy-
cle progression. We suggest that this was due to its ability to
prevent premature activation of other cell cycle kinases, includ-
ing cyclin A-Cdk2 and cyclin A-Cdc2, in the face of increased
and prematurely active cyclin E.
In contrast to the deleterious effects of cyclin ET393A in p21−/−
MEFs, the cyclin ET393A p21−/− mice developed normally. This
difference is probably attributable to the ongoing DNA damage
that is present in cultured MEFs. MEFs growing in normal tis-
sue culture conditions with 20% oxygen accumulate extensive
oxygen-mediated genetic damage that limits their replicative
life span, and respond to the oxygen damage through the acti-
vation of p53 that triggers the expression of p21 and cellular
senescence (Parrinello et al., 2003). Therefore, conditions that
induce the p53-p21 pathway are likely to be settings in which
the regulation of cyclin E by the T393 pathway is particularly
critical. In other words, under conditions of cellular stress, loss
of this pathway together with loss of p21 will result in severe
cell cycle abnormalities. Thus, exposure to genotoxic agents
or irradiation may uncover a tumor-prone phenotype in cyclin
ET393A p21−/− mice.
In a p53 null background, the effects of cyclin ET393A on cell
proliferation and genetic instability were evident, but its delete-
rious effect on cell proliferation was lost. This recapitulated the
phenotype that we observed in spontaneously immortalized
cyclin ET393A MEFs. The ability of cyclin ET393A to both increase
cell proliferation and increase genetic instability, albeit in spe-
cific genetic backgrounds, suggested that this mutation had
the potential to be oncogenic. We confirmed this hypothesis in
three ways. First, cyclin ET393A p53−/− MEFs were much more
susceptible to H-Ras-induced transformation in vitro than were
p53−/− MEFs expressing wild-type cyclin E. This was associ-
ated with a significant increase in genetic instability, with a
morphologic phenotype typical of highly transformed cells, and
with growth to a higher saturation density. Second, mice that
somatically activated a K-RasG12D allele showed an increased
rate of tumorigenesis if they also expressed cyclin ET393A, with
many of these tumors showing increased genetic instability byCANCER CELL : JULY 2005array CGH. Third, expression of cyclin ET393A in p53−/− mice
resulted in a significantly increased rate of tumorigenesis.
Cyclin E activity is controlled at multiple levels that include
gene transcription, at least two pathways of ubiquitin-depen-
dent proteolysis, interactions with CDK inhibitory proteins, and
regulatory phosphorylation on its CDK2 catalytic subunit. An
important hypothesis that emerges from our studies is that
misregulation of one pathway alone may not be sufficient for
cyclin E to become oncogenic. In the particular example re-
ported here, the ability of cyclin E to induce cell cycle abnor-
malities and genetic instability was greatly increased when the
T393A stabilizing mutation was combined with loss of the p53-
p21 pathway of CDK inhibition. If only a single pathway is mu-
tated, then this may be compensated for by the activity of the
other. That is, loss of p53-p21 promotes cyclin E turnover
through the Fbw7 pathway by increasing the catalytic activity
of cyclin E-cdk2. Conversely, if Fbw7-mediated degradation is
disrupted, then p53 and p21 restrict the activity of cyclin
E-cdk2. Thus, disruption of both the p53-p21 and Fbw7 path-
ways were necessary for cyclin E-cdk2 activity to reach onco-
genic levels. It will therefore be important to determine if
lesions in the other cyclin E regulatory pathways can similarly
combine to induce oncogenic cell transformation.
Experimental procedures
Antibodies
Antibodies were obtained from the following sources: affinity-purified poly-
clonal anti-cyclin E (Clurman et al., 1996); monoclonal anti-Grb-2 (Phar-
Mingen); polyclonal anti-phospho-p53 (Ser15) (Cell Signaling); and mono-
clonal anti-α-tubulin (Sigma).
Mice
The targeting vector for cyclin ET393A mice was generated from a genomic
clone encoding cyclin E1 (provided by P. Sicinski). See the Supplemental
Data available with this article online for details on vector construction and
primers. The targeting construct was linearized and electroporated into
mouse XY AK7 ES cells, and homologous recombinants were selected in
G418 (Gibco). Colonies were screened by PCR amplification and confirmed
by Southern blot hybridization. Two ES cell clones were used for blastocyst
injection of C57/B6J mouse embryos. Germline transmission was identified
in male chimaeras by PCR. The LoxP Neo cassette was excised by crossing
with Cre-expressing MORE mice (provided by P. Soriano). Cyclin ET393A
mice were backcrossed for greater than five generations into c57/Bl6 and
SJ129 backgrounds. Cyclin ET393A heterozygous mice were bred with het-
erozygous p21+/− (provided by P. Leder) (Deng et al., 1995) and p53+/− mice
(B6.129S2-Trp53tm1Tyj; Jackson Labs) in a pure C57Bl/6J background.
Cyclin ET393A mice were crossed with LA-2 mice (provided by T. Jacks)
(Johnson et al., 2001) in pure SJ129 background. Mice were aged until
moribund (up to 24 months). Statistical analysis of the Kaplan-Meier survival
curves was performed using log rank test.
Preparation of MEFs and tissue culture
Early passage primary MEFs were prepared as described (Malek et al.,
2001). Immortalized cells were passaged on a 3T3 protocol (Todaro and
Green, 1963) multiple times on independent derivatives of MEFs. Short-
term cell growth assays were performed in triplicate as previously described
(Smith et al., 2003). Cell synchronization and cell cycle analyses were per-
formed with serum-starved/contact-inhibited cells as previously described
(Malek et al., 2001). Cell and tissue lysates and Western blots were per-
formed as previously described (Besson et al., 2004). Cyclin E-associated
kinase activity was measured as previously described (Firpo et al., 1994).
Unfractionated and T cell-enriched splenocytes (R&D T cell enrichment
columns) were isolated from the spleens of age-matched mice (2–4 months)
and cultured as previously described (Firpo et al., 1994). Activation was
determined by expression of transferrin receptor (FITC-TfR; BD Immuno-45
A R T I C L Echemicals) and IL-2 receptor (PE-anti-CD25; BD Immunochemicals) by flow
cytometry using CellQuest software.
Activated H-RasG12V was transfected into MEFs with Fugene 6 (Roche),
together with a plasmid encoding CMV β-galactoside as control. Foci for-
mation was detected by crystal violet in plates cultured for 2 weeks. A
parallel plate was assayed for β-galactosidase-positive cells. MEFs stably
expressing activated H-RasG12V were generated by retroviral transduction
as previously described (Besson et al., 2004).
Cyclin E half-life determination was performed by both 35S-methionine
pulse labeling as described (Welcker et al., 2003) and cycloheximide (25
g/ml) treatment. Proteasome inhibition was performed by treatment with
MG-132 (100 m; Calbiochem) for 6 hr or with β-lactone (10 mM; Calbi-
ochem).
Cytogenetic and SKY studies
Exponentially growing MEFs were treated with colcemid (0.1 g/ml; Sigma)
for 25 min and harvested by trypsinization. Cell pellets were resuspended
in hypotonic buffer (0.3% KCl, 0.1% sodium citrate) and incubated 22 min
at 37°C. Cells were fixed with 0.5 ml Carnoy’s fixative (75% methanol, 25%
glacial acetic acid), pelleted, and resuspended into 5 ml Carnoy’s fixative.
Fixed cells were dropped onto slides, air dried, and G banded (Seabright,
1971) or C banded (Salamanca and Armendares, 1974). The banded and
unbanded preparations were stained with Wright’s stain. Chromosome
preparations were also hybridized with the SKY probe mixture from Applied
Spectral Imaging (ASI; Magdal Haemak, Israel) for 24 hr at 37°C according
to the manufacturer’s protocol. Following hybridization, the preparations
were counterstained with 4#,6-diamino-2-phenylindole (DAPI). The analysis
was carried out using a SpectraCubeSD 300 system supported by 1.2 visu-
alization and analysis software.
Array CGH
Mouse bacterial artificial chromosome (BAC) arrays providing a 1 Mb reso-
lution were produced by the Genomics Shared Resource, Fred Hutchinson
Cancer Research Center (FHCRC), as described (Loo et al., 2004). The
mouse BAC clone set was provided by A. Bradley, Wellcome Trust Sanger
Institute (Chung et al., 2004). Labeling of tumor and reference DNA (129
male) with Cy3 or Cy5, hybridization to BAC arrays, scanning, and data
analysis were performed as described (Loo et al., 2004).
Supplemental data
The Supplemental Data include Experimental Procedures and one table and
can be found with this article online at http://www.cancercell.org/cgi/
content/full/8/1/35/DC1/.
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